Analyses / SMCI
Down 9.67% today amid ITC patent probe and governance concerns; massive $60B+ backlog offset by execution & legal risks.
A free account reveals SMCI's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Massive $60B+ order backlog, 61.7% YoY revenue growth, 46.4% EPS growth, strong current ratio (5.2x), low P/S (0.77x) vs peers, tangible book value $37.28 vs price $25.70 suggest deep-value floor in hyper-growth AI infrastructure cycle.
▼ Bear Case
Down 61% from 52-week high ($62.36→$25.70); ITC patent investigation (Netlist memory tech), persistent governance issues, thin margins (4.77% net, 5.56% op), high beta (2.05), elevated EV/EBITDA (18.4x), backlog-to-revenue conversion risk, insider sells outpacing buys (178 vs 125 transactions).
Valuation
MIXED – Cheap on growth multiples; expensive on cyclical risk. — score 62/100
P/S 0.77x is attractive vs high-growth peers; P/E 13.5x fair for 46% EPS growth if sustained. However, EV/EBITDA 18.4x is elevated for 5.56% op margins. Book value ($10.61) vs price ($25.70) and tangible book ($37.28) show balance sheet resilience, but asset-light AI infrastructure plays typically command P/S 1.5-3x. Current valuation implies near-zero margin expansion or growth deceleration risk priced in.
Technical Levels
Support · $19.48 (52-week low) · $21.50 (Recent support / backtest zone) · $25.00 (Today's open area; round-number floor)
Resistance · $28.45 (Prev close; intraday high) · $31.00 (50-day MA proxy (not supplied)) · $40.00 (Psychological / 1-month recovery target) · $62.36 (52-week high)
Financial Health
Score 72/100. Liquidity is fortress-like (5.2x current, 3.15x quick); tangible book value suggests balance sheet has real asset backing. However, profitability margins are thin and balance-sheet composition (debt, deferred revenue) unknown. Insider selling (178 vs 125 buys) adds caution flag. Overall health score driven by liquidity + book value; absent debt data and with governance concerns, risk profile elevated.
Catalysts
| ITC Patent Investigation Resolution (Netlist Memory Tech) | Next 2-6 months (estimated) | HIGH – Dismissal lifts overhang; unfavorable ruling could force design changes, delay backlog conversion, pressure margins. Key unknown. |
| Next Quarterly Earnings & Backlog Update | Likely Q1 FY2025 (next 4-8 weeks, typical timing for SMCI) | HIGH – Backlog conversion rate, guidance, margin trend, governance commentary will reset investor confidence or deepen selloff. |
| AI / Datacenter Capex Cycle Sentiment | Ongoing (macro dependent) | MEDIUM – SMCI highly leveraged to AI server/infrastructure demand. Macro slowdown, chip glut, or customer capex pullback would crater backlog credibility. |
| Governance / Audit Committee Actions | 2-4 quarters | MEDIUM – Corporate governance reform, new auditor, or SEC inquiry outcomes will influence institutional confidence and stock re-rating. |
Risk Flags
See SMCI's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock SMCI free →Recent News
- Super Micro (SMCI) Faces ITC Patent Investigation Over Netlist Memory TechYahoo
- Super Micro Stock Falls Wednesday: AI Chip Probe Brings Support Test Into PlayBenzinga
- Super Micro Computer (SMCI) Stock Sinks As Market Gains: Here's WhyYahoo
- Super Micro Computer Booked More Than $60 Billion of Orders Last Quarter. The Entire Company Is Worth $19 Billion.Yahoo
- Super Micro: Governance Headwinds Persist - Backlog Conversion Meets FCF/Debt RisksSeekingAlpha
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full SMCI analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
SMCI FAQ
Is SMCI a buy right now?
Super Micro Computer Inc's current read is a growth_recovery_speculative setup with 55 confidence over a 3-6 months horizon. Valuation: MIXED – Cheap on growth multiples; expensive on cyclical risk.. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is SMCI overvalued?
MIXED – Cheap on growth multiples; expensive on cyclical risk. (valuation score 62/100). P/S 0.77x is attractive vs high-growth peers; P/E 13.5x fair for 46% EPS growth if sustained. However, EV/EBITDA 18.4x is elevated for 5.56% op margins. Book value ($10.61) vs price ($25.70) and tangible book ($37.28) show balance sheet resilience, but asset-light AI infrastructure plays typically command P/S 1.5-3x. Current valuation implies near-zero margin expansion or growth deceleration risk priced in.
What are the risks of buying SMCI?
Down 61% from 52-week high ($62.36→$25.70); ITC patent investigation (Netlist memory tech), persistent governance issues, thin margins (4.77% net, 5.56% op), high beta (2.05), elevated EV/EBITDA (18.4x), backlog-to-revenue conversion risk, insider sells outpacing buys (178 vs 125 transactions).